Find trials
Search tips

Fecal Microbiota Spores Live-Brpk Capsules And/or Fecal Microbiota Live-Jslm Suspension for Recurrent Clostridioides Difficile Infection

Overview

About this study

The purpose of this study is to evaluate the experience and clinical outcomes for patients with recurrent Clostridioides difficile infection (CDI) who received fecal microbiota spores live-brpk (VOWST) capsules and/or Fecal Microbiota live-jslm suspension (REBYOTA).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults > 18 years of age who have received fecal microbiota spores live bprk (VOWST) and fecal microbiota spores live-jslm (REBYOTA) for treatment of recurrent CDI.

Exclusion Criteria: 

  • Pediatric patients, healthy individuals who have not received fecal microbiota spores live bprk (VOWST) and fecal microbiota spores live-jslm (REBYOTA) for treatment of recurrent CDI.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/15/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sahil Khanna, M.B.B.S., M.S.

Open for enrollment

Contact information:

Elida Voth M.D.

(507) 266-0339

Voth.Elida@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20559477

Mayo Clinic Footer